SYRE
Spyre Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Spyre Therapeutics has 4 disclosed suppliers and 1 disclosed customer in SEC filings.
Last report1 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−0.56%
vs ±13.8% implied · ×0.04
shaded = implied · ▲▼ = realized
Spyre Therapeutics, Inc.
96.44
SentenceSubject to the terms of the contingent value rights agreement (the "CVR Agreement") we entered into with Equiniti Trust Company LLC (f/k/a American Stock Transfer & Trust Company LLC) as rights agent in connection with the Asset Acquisition, the upfront payment and contingent milestone payments actually received by us during the CVR term, net of expenses and adjustments, will be distributed to holders of our CVRs (as defined below) pursuant to the CVR Agreement.
SYRE 10-Kaccession 0001636282-26-000020
SentenceWe currently rely on our collaborations and licensing arrangements with third parties, including Paragon, for a substantial portion of our discovery capabilities and in-licenses.
SYRE 10-Kaccession 0001636282-26-000020
SentenceIn addition, we currently rely on foreign CROs and CMOs, including WuXi Biologics, and will likely continue to rely on foreign CROs and CMOs in the future.
SYRE 10-Kaccession 0001636282-26-000020
SentenceUnder the WuXi Biologics MSA, we are obligated to pay WuXi Biologics a service fee and all non-cancellable obligations in the amount specified in each work order associated with the agreement for the provision of services.
SYRE 10-Kaccession 0001636282-26-000020
SentenceOn July 27, 2023, we announced that we entered into an agreement to sell the global rights to pegzilarginase to Immedica for $15.0 million in upfront cash proceeds and up to $100.0 million in contingent milestone payments.
SYRE 10-Kaccession 0001636282-26-000020
Largest filed tie
—
Expected move
Inputs8Q avg ±5.6%·×1.47·rich
straddle ±12.9%
spot 96.56exp Nov 20ATM strike 95ATM straddle 14.70IV 80%